Inhibition of platelet aggregation by 1-methyl-4-phenyl pyridinium ion (MPP+) through ATP depletion: Evidence for the reduced platelet activities in Parkinson's disease

Platelets

Volumn 20, Issue 3, 2009, Pages 163-170

  Lim, Kyung Min ^a,b   Kim, Hyun Hee ^a   Bae, Ok Nam ^a   Noh, Ji Yoon ^a   Kim, Keun Young ^a   Kim, Sae Hwan ^a   Chung, Seung Min ^a   Shin, Sue ^c   Kim, Hyeon Yeong ^d   Chung, Jin Ho ^a  

^a Seoul National University   (South Korea)

^b AmorePacific Corporation   (South Korea)

^c Seoul National University Boramae Hospital   (South Korea)

^d Occupational Safety Health Research Institute   (South Korea)

Author keywords

ATP; MPP+; MPTP; Parkinson's disease; Platelet aggregation

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; ADENOSINE TRIPHOSPHATE; DEOXYGLUCOSE; GLUTATHIONE; LACTATE DEHYDROGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION;

1-METHYL-4-PHENYLPYRIDINIUM; ADENOSINE TRIPHOSPHATE; ANIMALS; BLOOD PLATELETS; CALCIUM; CELL SURVIVAL; COLLAGEN; DEOXYGLUCOSE; GLUTATHIONE; PARKINSON DISEASE; PLATELET AGGREGATION; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS;

EID: 67651155950     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.1080/09537100902721746     Document Type: Article

References (34)

1. Jankovic J. Parkinson's disease: Clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008;79:368-376.
2. Di Monte DA, Lavasani M, Manning-Bog AB. Environmental factors in Parkinson's disease. Neurotoxicology 2002;23:487-502.
3. Markey SP, Johannessen JN, Chiueh CC. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature 1984;311:464-466.
4. Jackson-Lewis V, Przedborski S. Protocol for the MPTP mouse model of Parkinson's disease. Nature Protocols 2007;2:141-151.
5. Dauer W, Przedborski S. Parkinson's disease: Mechanisms and models. Neuron 2003;39:889-909.
6. Dunigan CD, Shamoo AE. Identification of the major transport pathway for the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium. Neuroscience 1996;75:37-41.
7. Javitch JA, Uhl GR, Snyder SH. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Characterization and localization of receptor binding sites in rat and human brain. Proc Natl Acad Sci USA 1984;81: 4591-4595.
8. Greenamyre JT, Sherer TB, Betarbet R, Panov AV. Complex I and Parkinson's disease. IUBMB Life 2001;52: 135-141.
9. Parker Jr WD, Parks JK, Swerdlow RH. Complex I deficiency in Parkinson's disease frontal cortex. Brain Res 2008;1189: 215-218.
10. Chinta SJ, Rajagopalan S, Butterfield DA, Andersen JK. In vitro and in vivo neuroprotection by gamma-glutamylcysteine ethyl ester against MPTP: Relevance to the role of glutathione in Parkinson's disease. Neurosci Lett 2006; 402:137-141.
11. Urani C, Brambilla E, Santagostino A, Camatini M. 1-Methyl-4-phenyl-1,2, 3,6-tetrahydropyridine (MPTP) affects the actin cytoskeleton and calcium level of Swiss 3T3 mouse fibroblasts. Toxicology 1994;91:117-126.
12. Del Zompo M, Bernardi F, Bonuccelli U, Maggio R, Bajorek M, Arnone M, Corsini GU. Properties of 3H-MPTP binding sites in human blood platelets. Life Sci 1986;39:1885-1891.
13. Andrews RK, Berndt MC. Platelet physiology and thrombosis. Thromb Res 2004;114:447-453.
14. Serebruany VL. Selective serotonin reuptake inhibitors and increased bleeding risk: Are we missing something? Am J Med 2006;119:113-116.
15. Bakken AM, Staeffler A, Jorgensen HA, Holmsen H. Glycerophospholipid molecular species in platelets and brain tissues - are platelets a good model for neurons? Platelets 2006;17:484-492.
16. Stahl SM, Meltzer HY. The human platelet as a model for the dopaminergic neuron: Kinetic and pharmacologic properties and the role of amine storage granules. Exp Neurol 1978; 59:1-15.
17. Seyfert UT, Haubelt H, Vogt A, Hellstern P. Variables influencing multiplate whole blood impedance platelet aggregometry and turbidimetric platelet aggregation in healthy individuals. Platelets 2007;18:199-206.
18. Bae ON, Kim YD, Lim KM, Noh JY, Chung SM, Kim K, Hong S, Shin S, Yoon JH, Chung JH. Salsolinol, an endogenous neurotoxin, enhances platelet aggregation and thrombus formation. Thromb Haemost 2008;100:52-59.
19. Griffith OW. Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal Biochem 1980;106:207-212.
20. +-induced neurodegeneration and glutathione impairment in the nigrostriatal dopaminergic pathway. J Pineal Res 2002;32:262-269.
21. Kim KA, Lee JY, Park KS, Kim MJ, Chung JH. Mechanism of menadione-induced cytotoxicity in rat platelets. Toxicol Appl Pharmacol 1996;138:12-19.
22. 2+-independent secretion is dependent on cytoplasmic ATP in human platelets. FEBS Lett 1985; 191:283-286.
23. Holmsen H, Robkin L. Effects of antimycin A and 2-deoxyglucose on energy metabolism in washed human platelets. Thromb Haemost 1980;42:1460-1472.
24. Korten A, Lodder J, Vreeling F, Boreas A, van Raak L, Kessels F. Stroke and idiopathic Parkinson's disease: Does a shortage of dopamine offer protection against stroke? Mov Disord 2001;16:119-123.
25. Sharma P, Nag D, Atam V, Seth PK, Khanna VK. Platelet aggregation in patients with Parkinson's disease. Stroke 1991;22:1607-1608.
26. Marttila RJ, Rinne UK. Arteriosclerosis, heredity, and some previous infections in the etiology of Parkinson's disease. A case-control study. Clin Neurol Neurosurg 1976;79:46-56.
27. Mahaut-Smith MP, Ennion SJ, Rolf MG, Evans RJ. ADP is not an agonist at P2X(1) receptors: Evidence for separate receptors stimulated by ATP and ADP on human platelets. Br J Pharmacol 2000;131:108-114.
28. Grenegard M, Vretenbrant-Oberg K, Nylander M, Desilets S, Lindstrom EG, Larsson A, Ramstrom I, Ramstrom S, Lindahl TL. The ATP-gated P2X1 receptor plays a pivotal role in activation of aspirin-treated platelets by thrombin and epinephrine. J Biol Chem 2008;283:18493-18504.
29. Bertrand ME, Simoons ML, Fox KA, Wallentin LC, Hamm CW, McFadden E, De Feyter PJ, Specchia G, Ruzyllo W. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002;23:1809-1840.
30. +, or paraquat. Proc Natl Acad Sci USA 2008;105:15136-15141.
31. Lee WS, Tsai WJ, Yeh PH, Wei BL, Chiou WF. Divergent role of calcium on Abeta- and MPTP-induced cell death in SK-N-SH neuroblastoma. Life Sci 2006;78:1268-1275.
32. Absi E, Ayala A, Machado A, Parrado J. Protective effect of melatonin against the 1-methyl-4-phenylpyridinium-induced inhibition of Complex I of the mitochondrial respiratory chain. J Pineal Res 2000;29:40-47.
33. Oury C, Toth-Zsamboki E, Thys C, Tytgat J, Vermylen J, Hoylaerts MF. The ATP-gated P2X1 ion channel acts as a positive regulator of platelet responses to collagen. Thromb Haemost 2001;86:1264-1271.
34. 2+ in the human platelet. J Thromb Haemost 2007;5:910-917.